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Sepsis is one of the common causes of acute renal failure
(ARF). The objective of this study was to identify new
biomarkers and therapeutic targets. We present a new rat
model of sepsis-induced ARF based on cecal ligation and
puncture (CLP). We used this model to find urinary proteins
which may be potential biomarkers and/or drug targets.
Aged rats were treated with fluids and antibiotics after CLP.
Urinary proteins from septic rats without ARF and urinary
proteins from septic rats with ARF were compared by
difference in-gel electrophoresis (DIGE). CLP surgery elevated
interleukin (IL)-6 and IL-10 serum cytokines and blood nitrite
compared with sham-operated rats. However, there was a
range of serum creatinine values at 24 h (0.4–2.3 mg/dl) and
only 24% developed ARF. Histology confirmed renal injury in
these rats. Forty-nine percent of rats did not develop ARF.
Rats without ARF also had less liver injury. The mortality rate
at 24 h was 27% but was increased by housing the post-
surgery rats in metabolic cages. Creatinine clearance and
urine output 2–8 h after CLP was significantly reduced in rats
which died within 24 h. Using DIGE we identified changes in a
number of urinary proteins including albumin, brush-border
enzymes (e.g., meprin-1-alpha) and serine protease
inhibitors. The meprin-1-alpha inhibitor actinonin prevented
ARF in aged mice. In summary, we describe a new rat model
of sepsis-induced ARF which has a heterogeneous response
similar to humans. This model allowed us to use DIGE to find
changes in urinary proteins and this approach identified a
potential biomarker and drug target – meprin-1-alpha.
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Sepsis is one of the most common causes of acute renal
failure (ARF) and, despite extensive investigation, continues
to have a high mortality.1–3 There have been few successful
clinical trials although recent studies have shown that novel
therapies targeting coagulation (activated protein C) and
glucose control (intensive insulin therapy) can alter the
prognosis of humans with sepsis.4,5 New animal models that
better mimic human sepsis combined with advances in
proteomic techniques may lead to the discovery of more
biomarkers and novel therapeutic targets.
The cecal ligation and puncture (CLP) model is one of the
commonly used animal models of polymicrobial sepsis. Our
laboratory recently developed a clinically relevant model of
sepsis in aged mice that are treated, like patients, with fluid
resuscitation and broad-spectrum antibiotics.6,7 In this
model, the mice consistently develop ARF in the context of
multi-organ injury. This allowed us to demonstrate that the
novel anti-inflammatory drug, ethyl pyruvate, was effective at
reducing renal injury even when administered after induction
of sepsis.6,7 However, any mouse model has limitations
especially with regard to collection of biofluids such as urine.
Therefore, in this paper we develop and characterize a treated
CLP model in rats and obtain sufficient urine to discover
urinary proteins which may represent biomarkers or new
targets for drug development.
To investigate changes in the abundance of urinary
proteins we used two-dimensional (2D) difference in-gel
electrophoresis (DIGE). This technique is based on labeling
of protein samples with either Cy3 or Cy5 fluorescent dyes
then running both samples on the same 2D gel to eliminate
gel to gel variability. The Cy3- and Cy5-labeled proteins can
then be imaged and changes in protein abundance quantified.
The proteins which have changed can then be identified by
mass spectrometry. This technique has been successfully
applied in a range of scenarios such as the identification of
kidney inner medullary collecting duct proteins,8 markers of
liver toxicity,9 and cancer-specific proteins.10 In this paper,
we use DIGE to compare urinary proteins from septic
rats with ARF (responders) to septic rats without ARF
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(non-responders). An objective of this comparison was to
find new drug targets for sepsis-induced ARF, therefore we
tested the effect of an inhibitor of one of the urinary proteins
identified by DIGE.
RESULTS
Characterization of the fluid- and antibiotic-treated sepsis
model in aged rats (Group 1 – no urine collection)
CLP did not produce renal injury in young rats (unpublished
observation) so aged Sprague–Dawley rats (retired breeders)
were used. To develop a clinically relevant model, we treated
the animals with fluids and antibiotics at 6 and 18 h after
surgery (Figure 1). This time course was chosen because the
animals become unwell at around 6 h and we wanted to
mimic the time delay typically seen in humans between onset
of sepsis and presentation to a physician. A heterogeneous
response in renal function was seen in this model. There was
a wide range of serum creatinine values at 24 h post-CLP
(0.4–2.3 mg/dl) and 24% developed ARF defined as a twofold
increase in creatinine (X0.8 mg/dl, the sepsis-ARF group)
(Figure 2, white bars). Figure 2 also groups rats by the RIFLE
criteria, a staging classification for human ARF (Acute Dia-
lysis Quality Initiative, http://www.ADQI.net). Approximately
49% of the animals did not develop ARF (sepsis-no ARF
group) (creatinine o0.8 mg/dl). The mortality rate at 24 h
was 27%; these animals died without discernment of serum
creatinine at 24 h. This was a pattern that was similar to
humans, as about 30% of septic intensive care units patients
develop ARF, and the mortality rate from sepsis ranges from
26 to 82%.1–3 The heterogeneity of this model complicates
the testing of therapeutic agents, in contrast to our CLP
mouse model, which has a more consistent response.
However, the rat model heterogeneity was useful for
identifying pathophysiological differences between ‘respon-
ders’ (sepsis-ARF group) and ‘non-responders’ (sepsis-no
ARF group).
Effect of CLP on organ injury
Previously, we have shown significant multi-organ injury in a
similar CLP model with fluid and antibiotic treatment in
mice where X80% of all animals developed ARF.6 The new
CLP model in rats also showed multiple organ injury with a
difference observed between the septic-no ARF and septic-
ARF groups (Figure 3). The data presented in Figure 3 were
collected from rats which were not housed in a metabolic
cage (group 1). Liver injury was present as the enzymes
alanine transaminase, aspartate transaminase (AST) and
alkaline phosphatase were increased at 24 h after CLP. The
increase in alanine transaminase and AST was significantly
greater in rats with ARF.
Similar to the mouse model, lactate dehydrogenase (LDH)
and amylase in the rat model also increased after CLP,
amylase to a greater extent in the sepsis-ARF group (Figure 4).
Uric acid was slightly decreased 24 h after CLP, which
supports the absence of volume depletion in this model
(Figure 4).
Renal and hepatic injury
Kidney and liver sections were taken at 0, 8, and 24 h and
stained with periodic acid-Schiff reagent. Renal histology at
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Figure 1 | Experimental protocol. CLP surgery was performed at
time zero. Fluids (Fl) and/or antibiotics (Abx) were administered at 0,
6, and 18 h. Blood was drawn at 0, 8, and 24 h. Urine collections (6 h)
were taken from 22 to 16 h before and 2–8 h after CLP.
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Figure 2 | Heterogeneous outcomes in renal function 24 h after
CLP surgery. CLP surgery was performed on 63 rats without housing
in a metabolic cage (Group 1, white bars) and 32 rats with housing in
a metabolic cage (Group 2, black bars). Outcomes are shown as a
frequency distribution; Group 1 has a significantly different
distribution than Group 2 by w2 test P2o0.001.
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Figure 3 | Multiple organ injury after 24 h after CLP surgery.
(Group 1, n¼ 63) Indicators of organ injury expressed as a percent
change above sham are shown for rats that did not develop ARF
(white n¼ 31) and for rats that developed ARF at 24 h (black n¼ 15).
Values are mean7s.e. (*Po0.02 ARF vs no ARF).
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8 h did not show histological damage early after CLP
(Figure 4). At 24 h, histological injury was evident by the
loss of brush border, slight vacuolization, and exfoliated cells
(Figure 4c). Hepatic injury was also evident at 8 and 24 h by
decreased glycogen staining (not shown) with even greater
damage at 24 h evident by vesicular nuclei and opening of the
sinusoids (Figure 4e and f).
Time course of cytokine and nitrite response to sepsis
Induction of pro- and anti-inflammatory cytokines has been
well documented in sepsis.11 We investigated the time course
of the cytokine response by measuring interleukin (IL)-6,
IL-10 and Tumor necrosis factor (TNF)-a at 8 and 24 h after
CLP or sham surgery. The pro-inflammatory cytokine IL-6
and anti-inflammatory cytokine IL-10 were significantly
increased in all CLP animals compared to sham animals at
8 h (Figure 5a) and 24 h (Figure 5a) after surgery. There was
also a significantly greater increase in the animals that
developed ARF over the ones that did not. Serum TNF-a was
undetectable (o12.5 pg/ml) in all groups at 8 and 24 h (data
not shown).
Nitric oxide (NO) has been shown to be elevated in septic
patients, however, the role of NO in the pathophysiology of
sepsis is unclear.12 We measured nitrite in the blood as an
estimate of NO. Nitrite levels in the blood were altered after
CLP both at 8 and 24 h post-surgery (Figure 5c). Nitrite levels
were significantly increased above normal by 8 h after CLP
and an even greater increase was seen at 24 h.
Urinary changes after sepsis – Group 2
We investigated changes in urine output and creatinine
clearance by collecting rat urine in a metabolic cage, which
increased the death rate of the model from 27 to 62%
(Figure 2, black bars). The use of the metabolic cages
prevented the animals from being housed at 291C after
surgery as was carried out with the other animals. Also, with
the use of the cages, the animals were given fluids at 8 h
instead of 6 h. Other factors such as age, weight, surgical
technique, number of days housed, etc. could not explain this
effect. The use of the metabolic cage only induced a change in
the rates of ARF and death and otherwise renal histology,
cytokine, and liver enzyme responses were indistinguishable
between these groups (data not shown).
Urine output decreased almost immediately after surgery
in all septic animals as compared to pre-surgery urine output.
When animals were grouped by 24-h outcome, there was a
greater decrease in urine output in animals that did not
survive to 24 h than in the survivors, however, this difference
was not significant (Figure 6a). These findings are consistent
with previous observations that septic mice produce a
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Figure 4 | Organ histology. (a–c) Rat kidney and (d–f) liver sections
were stained with periodic acid-Schiff reagent at 0, 8, or 24 h after
CLP. Renal histological damage was evident at 24 h with loss of the
brush border, slight vacuolization (arrowheads), and exfoliated cells.
Hepatic histology revealed damage at 8 and 24 h and with decreased
staining and greater damage at 24 h was evident by vesicular nuclei
and opening of the sinusoids.
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Figure 5 | Effect of sepsis on cytokine and nitrite levels. Serum
cytokine levels were measured in serum in shams and at (a) 8 h and
(b) 24 h after CLP. Values are expressed for individual animals as the
square root. (a) #Po0.05, *Po0.007 sham vs IL-6 ARF rats; sham vs
IL-10 ARF, and no ARF rats. (b) #Po0.03, *Po0.002 sham vs IL-6 ARF
rats, and no ARF rats; sham vs IL-10 ARF rats.) (c) Non-degraded blood
nitrite was measured as a surrogate of NO. Sepsis increased nitrite
levels at 8 h and even greater at 24 h. Points are shown for animals
that did not develop ARF (white, n¼ 16) and for animals that
developed ARF (black, n¼ 2). (*Po0.001, 24 h vs normal).
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significantly reduced volume of urine shown by a new
magnetic resonance imaging technique.7 Changes in creati-
nine clearance were seen early after the onset of sepsis (Figure
6b). As expected, the decrease in creatinine clearance was
dependent upon the severity of renal injury at 8 h shown by
the reciprocal relationship between rising 8 h serum creati-
nine and decreasing creatinine clearance (not shown). The
early change in creatinine clearance was also related to the
24-h outcome as the animals that did not survive to 24 h had
a mean 40% decrease in creatinine clearance where as sham
animals and survivors had a mean 25% increase in creatinine
clearance (Figure 6b).
Urinary proteomics
We used electrophoresis to compare the urinary proteome
from three rats with sepsis but normal renal function (serum
creatinine before surgery¼ 0.570.03 mg/dl; at 8 h after CLP
surgery¼ 0.670.1 mg/dl (n¼ 3) with the urinary proteome
from three septic rats with ARF (serum creatinine before
surgery¼ 0.470.1 mg/dl; at 8 h after CLP surger-
y¼ 1.370.3 mg/dl (n¼ 3)). The urine was collected from
2 to 8 h after CLP surgery (sepsis-no ARF, urine volume
2.270.7 ml sepsis-ARF, urine volume 1.770.3 ml). In this
time period, there was a large variation in the amount of
protein excreted by each rat within the two groups (sepsis-no
ARF group, 0.3, 1.4, 7.6 mg; sepsis-ARF, 1.5, 2.5, 6.3 mg).
Initial studies showed that this variation was largely due to
differences in production of prostatic proteins. Figure 7
shows a 2D gel image of the abundant protein ventral
prostate-specific protein from two rats without ARF. The
amount released into the urine was clearly very different. To
manage this variability we pooled urine samples from three
rats without ARF and compared this with pooled urine
samples from three rats with ARF. In this time period, the
three rats without ARF excreted a total of 9.4 mg of urinary
protein. The three rats with ARF excreted a total of 10.3 mg
of urinary protein. Therefore, the amount of protein excreted
per group was similar.
After precipitation of the urinary protein, the amount of
protein excreted in the urine in 1.48 min was labeled with
Cy3 (no ARF) or Cy5 (ARF). This time period was chosen as
the amount of protein excreted in both groups was near to
50 mg, the optimal amount for minimal labeling with Cy dyes.
The samples were then separated by isoelectric focusing in
the first dimension and molecular weight in the second
dimension to produce a 2D gel image (Figure 8). Red spots
indicate an increased relative abundance in the sepsis-ARF
rats. Green indicates a decreased relative abundance and
yellow spots are unchanged in relative abundance. By pooling
the samples, the amount of prostatic protein excreted did not
change in relative abundance. Therefore, we could readily
detect changes in proteins associated with renal injury.
2D gel electrophoresis was performed in triplicate and,
using DeCyder software, spots were selected for identification
by matrix-assisted laser desorption/ionization-time-of-
flight–time-of-flight if there was a change in relative
abundance and the change was significant (Po0.05 by
t-test). In total, 97 spots were selected of which 30 were
correctly identified. Identification was considered correct if
the MS peptide mass fingerprinting score was above 95% and
the measured molecular weight and isoelectric point matched
the expected values (Table 1).
Three groups of proteins were found to change in relative
abundance with ARF (Figure 9). Circulating proteins such as
albumin were increased, serine protease inhibitors (SPIs)
were decreased and ‘kidney specific’ proteins were either
increased (aminopeptidase) or decreased (meprin-1-alpha).
Given the small number of differentially expressed protein
spots and fewer subsequently identified proteins, there are
limitations to this proteomic strategy, but it is suitable for
protein discovery as long as the candidate biomarkers are
subsequently validated.
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Figure 6 | Urinary changes. Urine was collected for 6 h before and
after CLP. (a) The percent change in the urine output from pre-
surgery to post-surgery is shown for sham-operated rats (white,
n¼ 8), rats that survived CLP surgery(gray, n¼ 10) and rats that did
not survive to 24 h post-CLP (black, n¼ 22). (b) The change in
creatinine clearance from pre-surgery to post-surgery in sham (white,
n¼ 8), and animals that survived (gray, n¼ 10) and did not survive to
24 h (black, n¼ 22). Values are mean7s.e. (*Po0.05 vs sham).
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Figure 7 | Region of 2D electrophoresis gels containing urinary
ventral prostate-specific protein from two septic rats without
ARF. (a) Rat produced 0.37 mg of urinary protein in 6 h. (b) Rat
produced 7.6 mg of urinary protein in 6 h. The increased excretion of
prostatic proteins contribute to the increased urinary protein
excretion in Rat B.
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We validated the 2D gel results by performing a western
blot for meprin-1-alpha on independently obtained samples.
Meprin was strongly excreted in sepsis-no ARF rats (Figure
10 – last three lanes) but not detected in urine from rats with
sepsis and ARF (Figure 10 – first three lanes).
Drug-target validation
Brush border enzymes changed in abundance and correlated
with renal injury. Actinonin, an inhibitor of the brush-border
enzymes (especially meprin-1-alpha) was given to the CLP
mouse model described by our lab previously6 at 0 and 6 h
after surgery (400 mg). The mouse model was used as renal
injury is more consistent than in rats and makes correct
detection of a positive or negative drug effect more likely
with a given number of animals. Mice treated with actinonin
had a lower serum creatinine compared with vehicle-treated
mice 24 h after CLP (Figure 11).
DISCUSSION
The new rat model of sepsis-induced ARF had a hetero-
geneous response that was similar to the human disease. This
heterogeneity allowed responders to be compared to non-
responders using proteomics to detect potential urinary
biomarkers and drug targets. Actinonin, a brush-border
enzyme inhibitor, protected renal function in our mouse
sepsis model, similar to data reported for ischemic renal
injury.13 This demonstrates the potential of proteomics in
drug-target discovery.
Model of sepsis-induced ARF that is clinically relevant to the
human disease
We developed a rat model of sepsis-induced ARF based on
the polymicrobial CLP model but with two distinct features
that may make this model clinically relevant. First, animals
were treated with fluid resuscitation and broad-spectrum
antibiotics, and second, aged rather than young rats were
used. Previous studies based on the CLP model have not
included fluid and antibiotic treatment, which is standard
treatment for septic patients. Fluid and antibiotic treatment
alters outcome after CLP and makes a rodent model more
consistent with clinical practice.14,15 In our rat model, fluid
and antibiotic treatment was not started until 6 h after CLP
to mimic the delay typically seen in the presentation of
human sepsis. The second distinct feature of this model was
the use of aged rats. Sepsis-induced ARF is more commonly a
disease of the elderly as those with sepsis-induced ARF are,
on average, older than those with other forms of ARF.16 The
prognosis of sepsis-induced ARF in the elderly is poor with
an increase in mortality with aging from 10% in children to
38.4% in those 485 years old.17 Aged rats were also used
because young rats either died or did not develop CLP-
induced ARF in our lab when treated with fluids and
antibiotics (unpublished observation). Saito et al., found
similar results in aged vs young mice using the CLP model.18
A unique feature of this model was the heterogeneous
response to sepsis that is similar to humans. In the animals
that survived, serum creatinine values ranged from 0.4 to
2.3 mg/dl and there was a 27% mortality rate at 24 h. Twenty-
four percent of the rats developed ARF, which is a pattern
similar to humans as 19–23% of moderate to severe septic
patients develop ARF.19 The mortality rate of 27% in our rat
model was also similar to humans. Hotchkiss et al. found that
the mortality rate in patients admitted to the intensive care
units with sepsis was nearly 30%.20 Therefore, our new rat
model is clinically relevant to the human disease as it closely
mimics the human response to sepsis. The reasons for the
variability in our model are not understood. Since the model
generates animals what have sepsis both without and with
ARF, the confounding effects of sepsis that are independent
of ARF can be isolated and studied. Also, the wide span in
disease severity allows potential disease biomarkers or
candidate mediators to be tested over a wide range of disease
severity. However, testing therapeutic agents in such a
variable model requires large numbers of animals, in part
because animals that do not develop ARF cannot be easily
distinguished from those that benefit from the agent.
In some animals, metabolic cages were used to collect the
urine. The use of the cages altered the response of the model
to increase the death rate from 27 to 62%. We hypothesize
that the use of the metabolic cage and housing the animals at
room temperature for the 24 h after surgery, rather than at
291C, caused additional stress on the animals which may
account for the increased death rate. These animals were
given fluids at 8 h instead of at 6 h, which may also be
partially responsible for the increased death rate.
The urine changes observed in the new sepsis model
demonstrated further similarities to the human disease. In
the rat model, sepsis-no ARF and sepsis-ARF groups had
oliguria and a decrease in creatinine clearance. These changes
were detected early after the onset of sepsis. The oliguria in
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Figure 8 | 2D electrophoresis gel comparing the urine of septic
rats without ARF to septic rats with ARF. Urine was pooled from
three animals for each group. Red indicates increased protein
abundance with ARF. Green indicates decreased protein abundance
with ARF. Yellow indicates no change in abundance. The numbers
correspond to the spot numbers of proteins identified in Table 1. The
spot labeled A is ventral prostate-specific protein which did not
change in abundance.
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the rat model was greater in the animals that did not survive
compared to the survivors, however, this was not significant.
This is similar to human septic ARF, as oliguria has been
found to be a predictor of mortality and the chance of
survival decreases once oliguria becomes resistant to volume
replacement.16,17 Creatinine clearance decreased early corre-
sponding to the severity of sepsis and renal injury. There was
an early decrease in the animals that did not survive to 24 h as
described in human sepsis.
This new sepsis model in rats resulted in multi-organ
injury despite antibiotic treatment and fluid resuscitation.
There were also differences in the severity of multi-organ
injury observed between the animals that did and did not
develop ARF. Enzyme markers of hepatic and pancreatic
injury showed greater elevation in the animals with ARF.
Renal injury was documented by serum creatinine and
histology. Despite some early rises in serum creatinine at 8 h,
renal injury was not detected by histology until 24 h. Hepatic
injury, however, was detectable by histology 8 h after CLP and
the severity of injury increased at 24 h. Liver injury was also
more severe in the animals that developed ARF. These are
similar findings to the temporal course seen in humans where
liver injury is detected early and renal injury is often one of
the final organs to fail.21
This model had histological evidence of ARF, which
has been detected in only a few rat CLP studies such as
Table 1 | Urinary proteins with changed abundance when septic rats with ARF were compared with septic rats without ARF
Spot
no.
Fold
change
with ARF Protein name
Accession
number
Measured
MW
Predicted
protein MW
Measured
pI
Predicted
protein pI
Peptide mass
fingerprinting
score (%)
Tandem mass
spectrometry
score (%)
1 2.6 Aminopeptidase M gi|601865 110 000 109 568 5 5.3 99.9 87.9
2 3.3 Kidney aminopeptidase M gi|13591914 110 000 109 779 5 5.3 99.9 98.1
3 2.9 Kidney aminopeptidase M gi|13591914 110 000 109 779 5 5.3 100 98.5
4 3.7 Alpha-2u-globulin gi|2119647 20 000 21 007 5 5.4 100 100
5 3.1 Alpha-2u globulin PGCL1 gi|22219450 25 000 21 009 5.5 5.9 100 100
6 2 Uromodulin; urmodulin
(Tamm–Horsfall protein)
gi|83945 09 80 000 73 751 4.5 4.8 100 94.8
7 1.4 Ezrin gi|17902245 110 000 54 254 6.5 6.2 100 99.9
8 1.8 Moesin (membrane-
organizing extension spike
protein
gi|462608 70 000 67 838 6 6.2 99.9 27.4
9 1.7 Moesin (membrane-
organizing extension spike
protein
gi|462608 70 000 67 838 6.5 6.2 99.9 87.4
10 3.2 Cadherin 1; E-cadherin gi|13786164 80 000 99 167 4.7 4.7 99.9 44.5
11 3.3 Meprin-1-alpha gi|6981196 80 000 86 168 5 5.6 99.9 98.7
12 3.6 Albumin gi|19705431 70 000 70 669 6 6.1 100 86.8
13 5.1 Unnamed protein product gi|57233 60 000 45 880 4.8 5.4 100 99.9
Kallikrein-binding protein
precursor
gi|92335 46 718 5.3 100 99.9
14 3.3 Unnamed protein product gi|57233 60 000 45 880 5 5.4 100 83.3
Kallikrein-binding protein
precursor
gi|92335 46 718 5.3 100 83.3
15 3.2 Unnamed protein product gi|57233 60 000 45 880 5 5.4 99.9
Kallikrein-binding protein
precursor
gi|92335 46 718 5.3 99.9
16 1.2 Alpha-1-antitrypsin
precursor
gi|203063 60 000 45 978 5 5.7 99.9
17 4.2 Serine protease inhibitor 2b gi|207042 50 000 36 817 5 5.2 98.2
18 3.7 Serine proteinase inhibitor 1 gi|92743 60 000 45 418 5 5.5 100 99.1
19 3.6 Serine proteinase inhibitor 1 gi|92743 50 000 45 418 5 5.5 89.5
20 4.2 Unnamed protein product gi|57233 50 000 45 880 5 5.4 99.6
21 4.2 Unnamed protein product gi|57233 50 000 45 880 5 5.4 97.3
22 4.1 Unnamed protein product gi|12854243 50 000 20 464 5 5.2 90.5
23 1.8 Put. beta-actin (aa 27–375) gi|49868 50 000 39 445 5.5 5.8 100 91
24 3.3 Contrapsin-like protease
inhibitor 3 precursor
gi|2507387 40 000 46 419 4.8 5.5 99.9 98.5
25 2.5 Contrapsin-like protease
inhibitor 3 precursor
gi|2507387 40 000 46 419 5 5.5 99.9 90.2
26 2.7 thyroid hormone-regulated
proteinase inhibitor – rat
gi|92880 40 000 31 901 5 5.7 99.9
27 4.1 Thyroid hormone-regulated
proteinase inhibitor – rat
gi|92880 40 000 31 901 5 5.7 100 90.1
28 6 Thyroid hormone-regulated
proteinase inhibitor – rat
gi|92880 50 000 31 901 5 5.7 99.9 86.4
29 7 Unnamed protein product gi|57233 50 000 45 881 5 5.4 100 98.6
30 2.7 Glandular kallikrien 8 gi|547791 40 000 29 565 5.5 5.6 99.1 99.7
ARF, acute renal failure; 2D, two-dimensional; MW, molecular weight; pI, isoelectric point.
Proteins were identified by matrix-assisted laser desorption/ionization-time-of-flight–time-of-flight. The spot numbers are as used in Figure 8. The change is expressed as fold
increase or decrease when ARF is compared to no ARF. A positive percentage indicates an increase with ARF, a negative indicates a decrease with ARF. The measured MW and
measured pI were determined from the 2D gel. Also shown is the predicted MW and pI. The identifications were made by peptide mass fingerprinting and tandem mass
spectrometry for most proteins and the scores are shown as a percentage.
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Huber-Lang et al.22 and Rhodes et al. (Rhodes GJ, Sandoval
RM, Molitoris BA: Intravital 2-photon visualization of
alterations in the rat kidney during sepsis. J Am Soc Nephrol
SA-PO704, 2004 (Abstract)) and in the mouse model
developed by our lab.6 Renal histological damage was
observed at 24 h after CLP; however, injury was delayed, as
no changes were detected 8 h after CLP. At 24 h, loss of the
brush border, slight vacuolization and exfoliated cells were
evident. Human renal histological damage after sepsis-
induced ARF is poorly described, however, Sato et al.23
found modest vacuolization and flattening of the brush-
border membrane in an ‘immediate (human) autopsy.’ This
may be similar to our rat model.
Induction of pro- and anti-inflammatory cytokines is well
documented in sepsis.24–26 We measured levels of IL-6, IL-10,
and TNF-a early (8 h) and late (24 h) to establish a time
course of cytokine response. Both IL-6 and IL-10 were
elevated and the animals that developed ARF also showed a
greater increase at each time point compared with the
animals without renal injury. Demirbilek et al.27, showed a
similar cytokine response in rats undergoing CLP surgery
with an early and greater increase in IL-6 and IL-10 at 9 h
compared to 18 h. Measurements of various cytokines in
septic patients by numerous groups have shown correlations
between levels of IL-6 with the severity of sepsis and
mortality.28 These findings are consistent with our rat model
as the rats with ARF were more severely injured and had
higher levels of IL-6. TNF-a was undetectable in all groups.
While TNF-a has been shown to be significantly elevated in
patients with sepsis, Damas et al.29, found that during acute
episodes of septic shock, TNF-a was only elevated for a few
hours and did not remain elevated. It is therefore possible
that TNF-a levels were elevated in our rat model but returned
to baseline by 8 h after CLP surgery.
We also measured levels of nitrite in the blood as an
indicator of NO production. Blood nitrite was elevated as a
result of sepsis at 8 and 24 h with a larger increase at 24 h.
Animals that developed ARF also showed a greater increase in
blood nitrite content at 8 h compared to the animals where
ARF was absent. NO has been proposed to be involved in the
pathogenesis of sepsis and multi-organ failure, although
there are conflicting reports as to its role and significance.30
In summary, our rat model has similarities with human
sepsis and its heterogeneous response can be utilized to
discover novel drug targets.
Biomarker and drug-target discovery using proteomics
In this paper, we used DIGE to investigate the urinary
proteome. This approach allowed comparison of urine from
septic rats without and with ARF. We discovered that a
number of proteins had significantly different expression
levels. Urinary albumin excretion was increased in rats with
ARF, consistent with other studies demonstrating increased
albuminuria in rodent models of sepsis-induced ARF.31
Mammalian plasma contains SPI regulating various processes
including coagulation, inflammation, and complement
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Figure 9 | Effect of ARF on urinary protein excretion in septic
animals. (a) Fold change of urinary proteins increased with ARF.
(b) Fold change of urinary proteins decreased with ARF. Black bars are
circulating proteins, white bars are renal proteins, hatched bars are
ERM (ezrin, radixin, moesin proteins), and gray bars are SPI.
Cr (mg/dl)   2.1
Sepsis–ARF              Sepsis–no ARF
1.4 1.3 0.7 0.5 0.7
Figure 10 | Immunoblot of urinary meprin-1-alpha. Each lane
represents urinary protein for a post-CLP rat. The protein amount
is normalized by time as per DIGE study. The creatinine value 8 h
post-CLP is shown.
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Figure 11 | Effect of actinonin on renal injury in mouse CLP
model. Renal injury induced by CLP in mice was inhibited by
actinonin, an inhibitor of the brush-border enzymes. Actinonin
(400mg) was given to mice at 0 and 6 h after CLP and reduced the
rise in serum creatinine (*Po0.05 n¼ 8 per group).
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activation.32 Using proteomics we found that urine from
septic rats with ARF had decreased amounts of SPI. This is in
keeping with the urinary levels of SPI reflecting the plasma
levels. Studies by other groups have found plasma levels of
SPI decreased with sepsis in rodents and humans and
correlated with severity of illness.33,34 After administration of
endotoxin, renal injury is more severe in mice lacking SPI.35
Pro-inflammatory cytokines and chemokines are elevated in
the kidneys of mice lacking SPI which suggests that SPI
action may not be solely inhibition of proteases but also
inhibition of cytokine and chemokine action. Treatment with
exogenous SPI improves survival in rodent models.33,34
Using DIGE and immunoblotting we also found changes
in tubular brush-border enzymes. Meprin is a brush-border
enzyme which plays a role in renal ischemia–reperfusion
injury. Meprin inhibition prevents hypoxic injury in vitro and
ischemia–reperfusion injury in vivo.13 Aminopeptidase is
established as a marker of renal injury after exposure to
nephrotoxins such as antibiotics and contrast agents.36,37
This protein is a brush-border enzyme and its increase in the
urine following sepsis-induced ARF reflects the loss of the
renal tubular brush border on histology.
However, gel-based proteomics has limitations. Within the
two groups (sepsis without ARF and sepsis with ARF) there
was considerable variability in the protein (mainly prostatic
proteins) excreted in the urine. The artifacts from this
variability were managed by pooling the samples, an
approach that has been validated for microarray analysis
and is especially valuable in studies when small numbers of
samples are used.38 Despite finding changes in the urinary
proteome, we did not detect established ARF biomarkers
such as lipocalin,39 CYR 61,40 and KIM-1;41 therefore, we
were unable to determine whether they changed in
abundance. Such false negatives may occur with gel-based
proteomics because of multiple reasons, such as difficulty in
detecting low-abundance proteins or the inability to solublize
membrane proteins. Even high-abundance, soluble proteins
may not be amenable to identification by mass spectrometry
because of technical limitations. Our data are by no means
exhaustive, considering the small sample size and pooling.
However, larger sample sizes and/or not pooling would likely
yield minimal numbers of proteins changed by ARF, in
addition to some false positives. Instead, approaches that are
more likely to complement DIGE and result in greater
coverage of the proteome might be needed, such as
separation by liquid chromatography prior to identification
by mass spectrometry or protein antibody arrays.42 Also
advances in mass spectrometry will increase the identification
rate of interesting proteins. Despite these limitations we
identified meprin-1-alpha as a potential biomarker for sepsis-
induced ARF. The urinary concentration of this protein
decreased with renal injury and meprin may be useful in a
multivariant combination with another biomarker. If one
urinary protein biomarker increases (e.g., KIM-1 or lipo-
calin) and meprin decreases with ARF then the ratio may
improve the ability to detect subtle renal injury.
Another objective of investigating the urinary proteome
was to discover novel drug targets for treatment of sepsis-
induced ARF. We used actinonin to inhibit brush-border
enzymes (especially meprin-1-alpha) as other groups have
demonstrated that this drug reduced renal injury in the
ischemia–reperfusion model of ARF.13 While the hetero-
geneity of our rat model is a strength for investigating
pathophysiology it is a weakness for testing therapeutics.
Therefore, we changed species and used our mouse model
which develops a more homogeneous amount of ARF in
response to CLP. Actinonin reduced renal injury in this
mouse model. Therefore, by using a heterogeneous animal
model and employing proteomics we succeeded in our
objective of identifying a novel drug target.
In summary, we describe a new rat model of sepsis-
induced ARF. This model has marked heterogeneity in
response. While this makes the model less suitable for testing
therapeutics it allows comparison of ‘responders’ to ‘non-
responders’ with potential for pathophysiological insights. By
using proteomics our study was able to detect changes in the
excretion of abundant urinary proteins which correlated with
the presence of sepsis-induced ARF. This led to our finding
that inhibition of brush-border enzymes with actinonin
prevented sepsis-induced ARF.
MATERIALS AND METHODS
Animals
Experiments were performed in aged (4–7 months), male Sprague–
Dawley rats weighing 450–550 g, purchased from Charles River
Laboratories Inc. (Wilmington, MA, USA). Free access to water and
food was allowed and animals were placed on a low potassium diet
after surgery (casein 180 g, cornstarch 200 g, sucrose 500 g, CaHPO4
10 g, MgSO4
. 7H2O 6 g, NaCl 8.8 g, Na2HPO4 6.8 g, KCl 3.5 g, vitamin
mix (ICN Biomedicals Inc., Costa Mesa, CA, USA) 10 g, corn oil
35 ml, peanut oil 35 ml, water 50 ml). All animals were treated in
accordance with the National Institutes of Health (NIH) guidelines
for use and care of research animals.
CLP sepsis-induced ARF – Group 1
Rats were anesthetized with 1.5% isoflurane. The abdomen was
shaved, cleaned with betadine solution, and a 3 cm incision was
made. The cecum was removed and ligated 0.75 cm from the cecal tip
with a 5–0 silk suture, punctured, and the cecal contents of the ligated
section was emptied into the peritoneal cavity. A second section was
ligated 1.5 cm proximal to the first ligature. The cecum was
punctured three times with an 18-gauge needle and gently squeezed
to ensure patency of puncture sites. The abdominal contents were
returned and the abdomen was closed in two layers with 4–0 nylon
sutures. Immediately after surgery, 24 ml/kg of pre-warmed normal
saline was given intraperitoneally. Animals were housed at 291C for
24 h after surgery. Animals were treated with 2/3 normal saline
(40 ml/kg) and broad-spectrum antibiotics (imipenem and cilastatin;
14 mg/kg) by subcutaneous injection at 6 and 18 h after surgery.
Buprenorphine was given as an analgesic at 0, 6, and 18 h (0.1 mg/kg,
subcutaneously). Blood was collected at 8 h for blood chemistry,
nitrite, and cytokine measurements. Animals were killed at 24 h after
surgery (Figure 1). At killing, blood was drawn, and the kidneys and
liver were harvested for histology (Group 1, n¼ 63).
Kidney International (2006) 70, 496–506 503
MK Holly et al.: Proteomics in rat model of sepsis-induced ARF o r i g i n a l a r t i c l e
To validate rat urinary proteins as potential drug targets a mouse
CLP model was used.6 C57BL/6 mice (11 months old ) were
anesthetized using isoflurane inhalation. After laparotomy, a 5–0 silk
ligature was placed 1 cm from the cecal tip. The cecum was
punctured twice with a 21-gauge needle and gently squeezed to
express a 1 mm column of fecal material. The abdominal incision
was closed in two layers with 6–0 nylon sutures. After surgery, 1 ml
of pre-warmed normal saline was given intraperitoneally. All
animals received a broad-spectrum antibiotic (imipenem/cilastatin;
14 mg/kg subcutaneously) at 6 h, and 1.5 ml of 3/4 normal saline was
administered at 6 and 18 h after surgery by subcutaneous injection.
There was an increase in body weight of 771% at 24 h, (n¼ 36).
Buprenorphine was given as an analgesic at 0, 6, and 18 h (0.1 mg/
kg, subcutaneously). Mice received either actinonin (400 mg
intraperitoneally at 0 and 6 h post-CLP) or normal saline vehicle.
At the time of killing, blood was collected by cardiac puncture for
measurement of serum creatinine by high-performance liquid
chromatography.
Blood chemistries and serum cytokine measurements
Serum creatinine was measured by picric acid-based colorimetric
autoanalyzer (Astra 8 autoanalyzer; Beckman Instruments, Full-
erton, CA, USA) and by high-performance liquid chromatography
method as previously described.43 Chemistry measurements of
serum blood urea nitrogen, alkaline phosphatase, alanine transami-
nase, aspartate transaminase, amylase, creatine kinase, lactase
dehydrogenase, albumin, total protein, and uric acid were measured
using an autoanalyzer (Hitachi 917, Boehringer Mannheim, Indiana-
polis, IN, USA). Serum levels of rat IL-6, IL-10, and TNF-a were
assayed by enzyme-linked immunosorbent assay (Quantikine, R&D
Systems Inc., Minneapolis, MN, USA).
Nitrite measurements
NO is difficult to measure because of its short half-life in the blood
and tissues.44 Nitrite is proposed to be a major vascular storage pool
of NO, so we measured nitrite in the blood as a surrogate of NO.45
To avoid nitrite oxidation by oxyhemoglobin and reduction by
deoxyhemoglobin that occurs ex vivo after blood collection, whole
blood nitrite concentration was measured by the method of Dejam
et al.46 Briefly, whole blood was drawn and immediately added to a
nitrite preservation solution (1.32 g K3Fe(CN)6, 4.5 ml H2O,
0.0625 g N-ethylmaleimide, 500ml Nonidet P40) in a ratio of 5:1.
The samples were stored at 801C until measured. Samples were
deproteinated with the addition of methanol (1:1) and centrifuged
for 2 min. Each sample (20–200 ml) was injected into a gas-phase
chemiluminescence NO analyzer (Sievers, Boulder, CO, USA) and a
peak corresponding to the nitrite concentration was measured.
Histology
Kidney and liver were fixed in 10% formalin, paraffin-embedded,
sectioned, (4m), and stained with periodic acid-Schiff reagent. Sections
were examined under  400 magnification for renal and hepatic
damage. Our histological criteria for renal damage were vacuolization
of proximal tubule cells, loss of the brush border and exfoliation of
cells into the tubular lumen. Hepatic sections were examined for
decreased staining, vesicular nuclei and opening of the sinusoids.
Urine collection and urinary creatinine measurements –
Group 2
A second group of animals were housed in a metabolic cage for
collection of urine before and after surgery. Urine was collected
before surgery (22 to 16 h) and 2–8 h after CLP surgery. Both
collections were at the same time of day to prevent changes caused
by circadian rhythms (Figure 1). To avoid urine changes caused by
giving 6-h fluids in the middle of urine collection, animals in the
metabolic cages were instead given fluids at 8 and 18 h. There was an
increase in body weight of 771% at 24 h (n¼ 6), which was not
significantly different between Groups 1 and 2 (P40.05). Urine was
collected on ice with protease inhibitors (0.1 mg/ml leupeptin,
0.1 mg/ml PMSF, 1mM sodium azide, in 1 M Tris pH 6.8) in a 1:10
ratio of buffer to urine. The urine was centrifuged at 100 g for 5 min,
the supernatant filtered (0.22 mm Millex-GS, Millipore, Billerica,
MA, USA), and stored at 801C. Urinary creatinine was measured
by an i-STAT portable clinical analyzer (Abbott Laboratories Inc.,
Abbott Park, IL, USA).
2D DIGE
We investigated changes in the urinary proteome that could
represent potential biomarkers and drug targets for ARF by
comparing urine from septic rats with normal renal function
(non-responders) to the urine from septic rats with ARF
(responders). Urinary protein was precipitated by addition of 50%
ice-cold acetone followed by centrifugation at 95 g for 5 min. The
protein pellet was solubilized in lysis buffer containing 30 mM Tris,
pH 8.8, 7 M urea, 2 M thiourea, 4% 3-[3-cholamidopropyl-1]di-
methylammonio)-1-propanesulfonate and the protein concentra-
tion was determined using the 2D Quant kit (Amersham,
Piscataway, NJ, USA). The amount of protein labeled from each
rat corresponded to the same duration of urine collection (see
Results). The samples were then minimally labeled with Cy3 and
Cy5 dyes as per manufacturer’s instructions (200 pmol per sample).
Cy3- and Cy5-labeled samples were mixed together and rehydration
buffer was added (7 M urea, 2 M thiourea, 4% 3-[3-cholamidopropyl-
1]dimethylammonio)-1-propanesulfonate, 0.5% pharmalytes
(Amersham), 40 mM dithiothreitol, and 0.002% bromophenol blue).
Experiments were run in triplicate; one of the triplicate experiments
had unlabeled urinary protein added to a final protein content of
500 mg. The mixed samples were then loaded on an immobilized pH
gradient strip (24 cm; pH 3–10 NL) for isoelectric focusing
according to the following protocol: 30 V for 14 h (active
rehydration), 500 V for 500 Vh, 1000 V for 1000 Vh, and 8000 V
for 66,667 Vh. Strips were equilibrated for 15 min in a solution
containing 50 mM Tris HCl, pH 8.8, 6 M urea, 30% glycerol, 2%
sodium dodecyl sulfate, 0.002% bromophenol blue, and 65 mM
dithiothreitol followed by a second 15-min equilibration with
iodoacetamide (25 mg/ml) instead of dithiothreitol. Strips were
briefly rinsed in 1 sodium dodecyl sulphate-polyacrylamide gel
electrophoresis buffer and applied to a 12.5% polyacrylamide gel for
electrophoresis at 5 W/gel for 30 min followed by 17 W/gel for 4 h.
Image acquisition and analysis
Images were scanned on a Typhoon 9400 variable mode imager
(Amersham Biosciences) at an excitation wavelength of 670/30
(maxima/bandwidth) for Cy5 (laser 633 – red) or 580/30 for Cy3-
(laser 532 – green) labeled samples. The laser power was adjusted to
avoid signal saturation. The resolution was 100 mm. Images were
then processed with DeCyder Differential In Gel AnalysisV4.0
software (Amersham Biosciences) to identify changes in spot
fluorescence intensities.
After protein spots were designated to be picked, the gel with
500 mg protein was fixed in 10% methanol and 7% acetic acid for 1 h
and incubated in SYPRO Ruby protein gel stain (Bio-Rad) for at
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least 2 h. Then it was washed in 10% methanol and 7% acetic acid
for 1 h. Next, the gel was scanned at an excitation wavelength of 610/
30 (laser 532) to visualize all proteins present in the gel. CyDye- and
SYPRO-derived images were matched using DeCyder Biological
Variation Analysis V4.00.07 software (Amersham Biosciences), from
which a pick list was generated.
Spot picking and protein processing
The Ettan Spot Handling Workstation was used to cut out the
selected protein spots from the 500mg protein gel, perform an in-gel
tryptic digestion, extract the peptides from the gel, and transfer the
digested proteins on to a matrix-assisted laser desorption/ioniza-
tion-time-of-flight/Pro (Amersham Biosciences) sample slide. Pep-
tides were analyzed using a 4700 Proteomics Analyzer (Applied
Biosystems) tandem mass spectrometer.
Western blotting
Urinary protein was precipitated by addition of 50% ice-cold acetone
followed by centrifugation at 95 g for 5 min. The proteins were
resuspended in Laemmli sample buffer then fractionated on a 7.5%
polyacrylamide gel and transferred to a nitrocellulose membrane.
The membrane was blocked in 5% rabbit serum in Tris-buffered
saline containing 0.1% Tween 20. The membrane was incubated with
1:500 meprin 1a primary antibody (Santa Cruz Biotech, CA, USA)
overnight then incubated with horseradish peroxidase-conjugated
donkey anti-goat immunoglobulin. The reaction products were
visualized by chemiluminescence (ECL-plus; Amersham) using
BioMax MR film (Eastman Kodak, Rochester, NY, USA).
Statistical analysis
All data are expressed as mean7s.e. Differences between groups
were analyzed for statistical significance by analysis of variance or
t-test. Different outcomes in renal function 24 h after CLP surgery
were evaluated by a w2 test. A P-value o0.05 was accepted as
statistically significant.
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